Abstracts tagged "Epidemiology"

Abstract Number: 1621 • ACR Convergence 2025
Temporal Association Between Viral Positivity Rates and Kawasaki Disease Incidence at a Large Tertiary Center
Jessica Nguyen¹, Duc Nguyen¹, Ankona Banerjee², Kenneth Nobleza², Denver Niles² and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis associated with the development of coronary artery aneurysms predominantly affecting children less than 5 years of age.…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 1024 • ACR Convergence 2025
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Marta Ruiz-Valdepeñas Almansa¹, CLARA DE MIGUEL², DALIFER FREITES³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Olga Sanchez Pernaute⁵, fredeswinda Romero-Bueno⁶, Mª Jesus Rodriguez-Nieto⁷, Rosalia Laporta⁸, Hilda Godoy Tundidor⁹, Jesús Loarce¹⁰, Juan A Rigual¹¹ and lydia Abasolo Alcazar¹², ¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Clinica Universidad de Navarra, Madrid, Madrid, Spain, ⁶University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ⁷Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁸Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Hospital Universitario puerta de hierro, Madrid, Spain, ¹⁰HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…
Abstract Number: 0745 • ACR Convergence 2025
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Eugenio de Miguel, Natalia López-Juanes, Maria-Eugenia Miranda-Carus, Carlota Ureta, Chamaida Plasencia-Rodríguez and Irene Monjo Henry, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Traditionally, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) had been considered a hallmark of GCA and both are included in the 2022…
Abstract Number: 0324 • ACR Convergence 2025
Bile Acids Metabolism in Symptomatic Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study and Genetics of OA Consortium
Jiatian Li¹, Jing Ye¹, Tuo Yang¹, david Hunter², Weiya Zhang³, Michael Doherty³, Yuqing Zhang⁴, Zidan Yang¹, Hui Li¹, Yilun Wang¹, Dongxing Xie¹, Ziying Wu⁵, Wei Li¹, Zeqin Wen¹, Changjun Li¹, Chao Zeng¹, Guanghua Lei¹ and Jie Wei¹, ¹Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ³School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Xiangya Hospital, Central South University, Chang Sha, China (People's Republic)
Background/Purpose: Although gut microbiome dysbiosis has been implicated in symptomatic hand OA (SHOA), the potential contribution of bile acids (BAs), key metabolites in host-microbiota interactions,…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 2545 • ACR Convergence 2025
Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Valeria Manfrè¹, elena treppo², Maria Pillon³, Maria De Martino⁴, Cinzia Fabro⁵, Miriam Isola⁴, Martina Fabris⁶, Francesco Curcio⁶ and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, Udine, Italy, ⁴Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁶Institute of Clinical Pathology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy
Background/Purpose: Cryoglobulinemic vasculitis (CryoVas) is a rare immune-complex-mediated disorder, often associated with hepatitis C virus (HCV) infection, autoimmune diseases (ADs), or other etiologies. Despite its…
Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Joshua Skydel¹, Anna Leland², Reshma Ramachandran³, Fotios Koumpouras³ and Joshua Wallach², ¹Yale-New Haven Hospital, New Haven, CT, ²Rollins School of Public Health, Atlanta, GA, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…
Abstract Number: 1887 • ACR Convergence 2025
Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong
Danting zhang¹, jiaxin S. Wu¹ and Desmond Yat-Hin Yap², ¹The University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong
Background/Purpose: Advancements in immunosuppressive treatments and general medical care in the past two decades have influenced the disease burden and outcomes of patients with systemic…
Abstract Number: 1584 • ACR Convergence 2025
Evaluation of Adverse Childhood Experiences in Systemic Sclerosis: Prevalence and Patient Characteristics
Samuel Good¹, Nahal Ghanoongooi¹, Ju Young Lee², Arissa Young³ and Elizabeth Volkmann¹, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ³UCLA, Los Angeles, CA
Background/Purpose: There is growing evidence that trauma, and in particular adverse childhood experiences (ACEs), play a role in the pathogenesis and exacerbation of systemic autoimmune…
Abstract Number: 1312 • ACR Convergence 2025
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Elodie Portier¹, Olivier Fogel², Terkia Medkour³, Sophie Hecquet³ and Jérôme AVOUAC³, ¹Rheumatology department, Bicetre hospital, Le Kremlin Bicetre, France, ²AP-HP, Paris, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…
Abstract Number: 1018 • ACR Convergence 2025
Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
José Gomez-Puerta¹, Cristian Tebe², Maria Grau³, Beatriz Frade Sosa⁴, Juan Camilo Sarmiento-Monroy⁵, Cristina Carbonell-Abella⁶, Daniel Martinez-Laguna⁷, Patricia Corzo⁸, Raimon Sanmartí⁹ and J. Antonio Aviña-Zubieta¹⁰, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Instituto de Investigación Germans Trias i Pujol, Badalona, Spain, ³University of Barcelona, Barcelona, Spain, ⁴Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁵Hospital Clínic Barcelona, Barcelona, Spain, ⁶Medicina Familiar y Comunitaria, Centro de Salud Vía Roma, Barcelona, Spain, ⁷Grup de recerca en malalties prevalents de l'Aparell locomotor en Atenció Primaria (GREMPAL), ICS, Barcelona, Spain, ⁸Rheumatology Department, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: The differences in lupus-related mortality reported in population studies are partly explained by racial disparities and access to healthcare. However, population-based data from universal…
Abstract Number: 0735 • ACR Convergence 2025
A Real-World Study from the Greater Paris Clinical Data Warehouse
Aïcha Kante¹, Olivier Hassanaly², Geoffroy Peyrac³, David Saadoun⁴, Cacoub Patrice⁴, Alexis REGENT⁵, Benjamin Terrier⁶, Luc Mouthon⁷, Arsène Mekinian⁸, Karim Sacré⁹, Jean-François Alexandra¹⁰, Sébastien Abad¹¹, Robin Dhote¹¹, Cécile goujard¹², Damien Sène¹³, Stéphane Mouly¹⁴, Baptiste Hervier¹⁵, Olivier Bory¹⁶, Elisabeth Aslangul¹⁶, Isabelle Mahé¹⁶, Anne Couvelard¹⁷, Yann Nguyen¹⁸, Agnès Lefort¹⁸, Sophie georgin-Lavialle¹⁹, Olivier Steichen¹⁹, Viet-Thi Tran²⁰ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Unité de recherche clinique, AP-HP, Hôpital Saint Louis, F⁷⁵⁰¹⁰, Paris, France, Paris, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ⁵Hopital Cochin, Paris, France, ⁶Cochin Hospital, Paris, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁹Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ¹⁰Internal Medicine, Hôpital Bichat, APHP, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP); Université Paris ¹³, Sorbonne Paris Cité, Bobigny, France, Bobigny, France, ¹²Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁵Internal Medicine Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, Louis-Mourier Hospital, AP-HP, Colombes, France, Colombes, France, ¹⁷Pathology Department, Bichat and Beaujon Hospitals, AP-HP, FHU MOSAIC, Université Paris Cité, Paris, France, Paris, France, ¹⁸Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris; and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) relapses are frequent and often require therapeutic intensification in the form of glucocorticoids (GC) increase. GCA management has significantly evolved…
Abstract Number: 0322 • ACR Convergence 2025
Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Shike Xu², Timothy McAlington³, John Haran⁴, Julieann Patarini⁴ and Bing Lu⁵, ¹University of Massachusetts Chan Medical School, Marlborough, NH, ²University of Connecticut Health Center, Farmington, CT, ³UMass Chan School of Medicine, Arlington, MA, ⁴UMass Chan Medical School, Worcester, MA, ⁵UConn Health Center, Newton, MA
Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the…
Abstract Number: 1507 • ACR Convergence 2025
Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
Sasha Bernatsky¹, Sharon Dowell², Brittany Banbury³, Jeffrey Curtis⁴, Grace Wright⁵, Emily Holladay⁶, Amy Mudano⁷, Cristiano Moura⁸ and Gail Kerr⁹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²NEA Baptist Memorial Hospital, Jonesboro, AR, ³Mount Sinai Beth Israel, Brooklyn, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Grace C Wright MD PC, New York, NY, ⁶University of Alabama at Birmingham, Edmond, OK, ⁷Foundation for Advancing Science, Technology, Education and Research (FASTER), Birmingham, AL, ⁸Research Institute of the McGill University Health Center, Montréal, Canada, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Since SLE is associated with significant morbidity and healthcare burden, estimates of SLE incidence are needed to inform research and public health initiatives, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].